Friday, July 10, 2026
🇺🇸 FDA

Intelligence · Clinical pipeline

Phase II Pipeline Programs

Proof-of-concept and dose-finding clinical programs in Phase II development.

Programs 7,238
Sponsors 1,771
Drugs 4,798

Quick answer

NovaPharmaNews tracks 7,238 phase ii pharmaceutical pipeline programs from ClinicalTrials.gov. Proof-of-concept and dose-finding clinical programs in Phase II development.

Top sponsors

Pipeline programs

Page 12 of 151

  1. APHP200175

    Pari Pharma GmbH

    subarachnoid hemorrhages of aneurysmal origin (HSAa)

    phase 2 small molecule active

    1 trial

  2. APHP210084

    Pari Pharma GmbH

    first suspected infection with Mycobacterium tuberculosis in the lungs

    phase 2 small molecule active

    1 trial

  3. APHP210416

    Pari Pharma GmbH

    Degenerative shoulder rotator cuff tendinopathy

    phase 2 small molecule active

    1 trial

  4. APHP211000

    Pari Pharma GmbH

    PR3-ANCA granulomatosis with polyangiitis (Wegener’s)

    phase 2 small molecule active

    1 trial

  5. APHP211026

    Pari Pharma GmbH

    Systemic sclerosis

    phase 2 small molecule active

    1 trial

  6. APHP211176

    Pari Pharma GmbH

    Recently diagnosed non favorable Acute Myeloid Leukemias

    phase 2 small molecule active

    1 trial

  7. APHP220273

    Pari Pharma GmbH

    Adult patients aged 18 and over with unicentric hyalino-vascular Castleman's disease

    phase 2 small molecule active

    1 trial

  8. APHP220673

    Pari Pharma GmbH

    newly diagnosed or relapsing deep venous thrombosis related to Behçet’s syndrome

    phase 2 small molecule active

    1 trial

  9. APHP220729

    Pari Pharma GmbH

    Hepatocellular carcinoma

    phase 2 small molecule active

    1 trial

  10. APHP220808

    Pari Pharma GmbH

    Fulminant myocarditis

    phase 2 small molecule active

    1 trial

  11. APHP220916

    Pari Pharma GmbH

    -women with an inflammatory HCA proven at histology and with at least one inflammatory HCA of more than 5 cm. -male with at least one inflammatory HCA proven at histology whatever the size and considered as non resectable by the multidisciplinary tumor board

    phase 2 small molecule active

    1 trial

  12. APHP220934

    Pari Pharma GmbH

    AXIAL SPONDYLOARTHRITIS

    phase 2 small molecule active

    1 trial

  13. APHP221107

    Pari Pharma GmbH

    Healthy volunteers : Healthy adults with no history of gastrointestinal disease Patients with IBD in remission

    phase 2 small molecule active

    1 trial

  14. APHP221166

    Pari Pharma GmbH

    gram-negative bacillus pneumonia acquired during mechanical ventilation in patients receiving Extracorporeal Membrane veno-arterial oxygenation

    phase 2 small molecule active

    1 trial

  15. APHP230701

    Pari Pharma GmbH

    paraneoplastic sensory neuropathy with anti-Hu antibodies

    phase 2 small molecule active

    1 trial

  16. APHP230821

    Pari Pharma GmbH

    NEUROENDOCRINE CELLS HYPERPLASIA OF INFANCY

    phase 2 small molecule active

    1 trial

  17. APHP230831

    Pari Pharma GmbH

    Folliculitis decalvans

    phase 2 small molecule active

    1 trial

  18. APHP230845

    Pari Pharma GmbH

    Amyotrophic lateral Sclerosis

    phase 2 other active

    1 trial

  19. APHP230848

    Pari Pharma GmbH

    Non-infectious active cryoglobulinemia vasculitis who are either refractory or intolerant to Rituximab

    phase 2 small molecule active

    1 trial

  20. APHP231308

    Pari Pharma GmbH

    Major patients intoxicated by functional toxicant(s), hospitalized in intensive care and intubated.

    phase 2 small molecule active

    1 trial

  21. APHP240512

    Pari Pharma GmbH

    glioblastoma

    phase 2 small molecule active

    1 trial

  22. APHP240923

    Pari Pharma GmbH

    Sepsis

    phase 2 small molecule active

    1 trial

  23. APHP241595

    Pari Pharma GmbH

    The study population includes adult ICU patients with a hospitalization of more than 48 hours. We have chosen to include patients with or without mechanical ventilation, as sleep disorders affect all ICU patients after 48 hours.

    phase 2 small molecule active

    1 trial

  24. API-E004-CL-A

    Amphastar France Pharmaceuticals

    Asthma

    phase 2 small molecule terminated

    1 trial

  25. API-E004-CL-B4

    Amphastar France Pharmaceuticals

    Asthma

    phase 2 small molecule terminated

    1 trial

  26. API-EAB-2024-01

    Lacuna Pharma Pty Ltd

    Allergies

    phase 2 small molecule active

    1 trial

  27. API-EAD-2024-01

    Lacuna Pharma Pty Ltd

    Allergies

    phase 2 small molecule active

    1 trial

  28. API-EAD-2024-01

    Advanced Accelerator Applications

    Allergies

    phase 2 small molecule active

    1 trial

  29. API-EAL-2024-01

    Advanced Accelerator Applications

    Allergies

    phase 2 small molecule active

    1 trial

  30. API-EAO-2025-01

    Lacuna Pharma Pty Ltd

    Allergies

    phase 2 small molecule active

    1 trial

  31. APISLIT-DD-D-2025-01

    Advanced Accelerator Applications

    Allergic rhinitis/rhinoconjunctivitis caused by dust mite allergy

    phase 2 small molecule active

    1 trial

  32. APISLIT-DD-G-2025-01

    Lacuna Pharma Pty Ltd

    Allergic rhinitis/rhinoconjunctivitis caused by grass polen allergy

    phase 2 small molecule active

    1 trial

  33. APL-2

    Apellis Europe B.V.

    Warm Autoimmune Hemolytic Anemia

    phase 2 small molecule completed

    1 trial

  34. APL-2

    Apellis Europe B.V.

    IgA Nephropathy

    phase 2 small molecule completed

    1 trial

  35. APL-3007, pegcetacoplan (APL-2)

    Apellis Europe B.V.

    Geographic Atrophy Secondary to Age-related Macular Degeneration

    phase 2 small molecule active

    1 trial

  36. APL-9

    Apellis Europe B.V.

    COVID

    phase 2 small molecule completed

    1 trial

  37. APL2-PNH-209

    Lacuna Pharma Pty Ltd

    Paroxysmal Nocturnal Hemoglobinuria

    phase 2 small molecule active

    1 trial

  38. APLOaß-NB

    Istituto Gentili S.r.l.

    Patient affected by high risk Neuroblastoma relapsed or in progression after first line treatment.

    phase 2 small molecule active

    1 trial

  39. APO010

    Allarity Therapeutics

    Relapsed/Refractory Multiple Myeloma

    phase 2 small molecule terminated

    1 trial

  40. APR-246

    Aprea Therapeutics

    Melanoma

    phase 2 small molecule terminated

    1 trial

  41. APR-246

    Aprea Therapeutics

    Myelodysplastic Syndrome

    phase 2 small molecule completed

    1 trial

  42. APR-246

    Aprea Therapeutics

    Acute Myeloid Leukemia or Myelodysplastic Syndromes

    phase 2 small molecule completed

    1 trial

  43. APR-246

    Aprea Therapeutics

    Myelodysplastic Syndrome With Gene Mutation

    phase 2 small molecule active

    1 trial

  44. APR-246

    Aprea Therapeutics

    Platinum Sensitive Recurrent High-grade Serous Ovarian Cancer With Mutated p53

    phase 2 small molecule completed

    1 trial

  45. APR-246

    Aprea Therapeutics

    High-grade Serous Ovarian Cancer

    phase 2 small molecule completed

    1 trial

  46. APR-246 (eprenetapopt) + Acalabrutinib in CLL

    Aprea Therapeutics

    Non Hodgkin Lymphoma

    phase 2 small molecule terminated

    1 trial

  47. APR-246 (eprenetapopt) + Pembrolizumab

    Aprea Therapeutics

    Bladder Cancer

    phase 2 small molecule completed

    1 trial

  48. APX005M

    Pyxis Oncology

    Melanoma

    phase 2 small molecule terminated

    1 trial

Frequently asked questions

How many Phase II pipeline programs are in the directory?

7,238 published programs match this development stage in our ClinicalTrials.gov index.

What defines this pipeline stage?

Phase and status reflect ClinicalTrials.gov registry fields at last sync. See our clinical trial phases reference for methodology.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.